RiverVest Closes Raise of $184.4 Million on Fourth Life Sciences Fund

Fund IV was oversubscribed.

Life sciences venture capital firm RiverVest Venture Partners has announced the final closing of RiverVest Venture Fund IV, L.P., reaching $184.4 million in capital commitments in an oversubscribed fundraise. RiverVest Fund IV marks the firm’s fourth dedicated life sciences fund, bringing its total assets under management as of Sept. 30 to $753 million.

“Since its initial closing late last year, RiverVest Venture Fund IV has invested in eight high potential companies, including founding or co-founding three,” said RiverVest Managing Director John McKearn, Ph.D.

Earlier RiverVest Funds II and III have each provided net internal rates of return to their Limited Partners of over 20% per annum as of Sept. 30. That puts those funds’ performance in the top 5% of all venture funds started in the same respective vintage years according to Cambridge Associates’ U.S. Venture Capital Index, which benchmarks over 1,500 institutional-quality venture capital funds.

“We are pleased that Fund IV exceeded our target,” said RiverVest co-founder and managing director Jay Schmelter. “It enables us to continue executing our strategy for generating top-quartile investor returns.”

Schmelter credits RiverVest’s success to the firm’s dual focus on developing biopharma and medical device products that treat high, unmet medical needs while simultaneously attracting a buyer or being ready for an IPO within three to five years of the initial investment.

Mentioned in this Article

Stories published by EQ Staff indicate that the article has been produced by multiple authors or adapted from a press release that's been sent to the editorial team. If you'd like to submit a press release for consideration or please join the EQ Accelerate program. Feel free to drop us a line to learn more. Press releases are not guaranteed paid for placements and are selected for publishing on a merit basis.